Table 1.
Clinical characteristics and vancomycin concentrations in cerebrospinal fluid
| Subject number |
Age (years) |
Sex | Weight (kg) |
Dose* (mg/kg/dose) |
Dosing interval* (h) |
Days of vancomycin therapy |
Serum creatinine* (mg/dL) |
Ventricular CSF culture |
Vancomycin MIC (mg/L) |
CCSF (mg/L) |
Time after last dose (h) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.2 | M | 1 | 30 (30, 30) | 11 (8, 12) | 4 | 0.12 (0.10, 0.20) | Negative | NA | 0.98 | 5.0 |
| 0.71 | 10.0 | ||||||||||
| 2 | 0.3 | F | 6 | 18 (15, 20) | 7 (4, 18) | 18 | 0.27 (0.20, 0.40) | E. coli | NA | 0.67 | 7.5 |
| 3 | 1.7 | M | 10 | 21 (19, 21) | 8 (7, 24) | 27 | 0.35 (0.20, 0.50) | MRSA E. coli |
0.75 NA |
1.02 | 4.5 |
| 1.12 | 4.6 | ||||||||||
| 1.15 | 14.5 | ||||||||||
| 4 | 4.3 | F | 12 | 17 (15, 20) | 8 (6, 11) | 8 | 0.22 (0.20, 0.30) | Negative | NA | 0.31 | 9.5 |
| 5 | 4.4 | M | 17 | 18 (15, 21) | 13 (6, 24) | 23 | 0.69 (0.40, 1.00) | MRSA | 1 | 4.79 | 7.0 |
| 9.13 | 8.0 | ||||||||||
| 6 | 10.4 | F | 30 | 20 (17, 22) | 9 (6, 59) | 23 | 0.51 (0.40, 0.70) | Gordonia sp/Rhodococcus sp group | Unknown§ | 3.01 | 7.0 |
| 7 | 14.8 | M | 53 | 19 (19, 19) | 8 (5, 24) | 9 | 0.80 (0.70, 0.90) | Negative¥ | NA | 6.60 | 4.0 |
| 8 | 17.3 | F | 116 | 11 (9,13) | 7 (5, 16) | 16 | 0.60 (0.50, 0.70) | CONS | 2 | 0.06 | 5.3 |
| Median (range) | 4.3 (0.2, 17.3) | 4 M (50%)** | 14 (1, 116) | 19 (11, 30) | 8 (7, 13) | 17 (4, 27) | 0.43 (0.13, 0.82) | 1.07 (0.06, 9.13) | 7.0 (4.0, 14.5) |
*
mean values and range over the vancomycin therapy,
**
n(%),
§
the identified bacteria was susceptible to vancomycin but the minimal inhibitory concentration was not available;
¥
CSF sampled through lumbar puncture
F indicates female; M, male; CCSF, vancomycin concentration in cerebrospinal fluid; CONS, coagulase negative staphylococcus sp; E. coli, Escherichia coli; MIC, minimal inhibitory concentration; MRSA, methicillin resistant Staphylococcus aureus; NA: not applicable